
The Surging Star: Why Travere Therapeutics Stole the Limelight
Travere Therapeutics Inc. saw its stock rise by 12.56 percent, reaching $23.75, amid a quiet Wall Street trading day. The stock surge is driven by optimism surrounding Filspari, a treatment for the rare kidney disorder focal segmental glomerulosclerosis (FSGS). Travere plans to